Stock EVAX EVAXION BIOTECH A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
4.13 USD -0.24% Intraday chart for Evaxion Biotech A/S +0.49% -39.77%
Apr. 17 Evaxion Announces Phase 2 Clinical Trial Update CI
Apr. 11 European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evaxion Announces Phase 2 Clinical Trial Update
CI
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
AQ
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024.
CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower
MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
MT
ADRs End Lower; Meta Data Slides 22%
DJ
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading
MT
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies; Shares Jump
MT
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy From Neutral, Price Target is $8
MT
Transcript : Evaxion Biotech A/S, 2023 Earnings Call, Apr 02, 2024
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
AQ
Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
CI
16 APRIL 2024 AT 15:00 (CEST) - Form 6-K
PU
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EVAX Stock
  4. News Evaxion Biotech A/S